Population Pharmacokinetics of Anidulafungin in Critically III Patients

Luque, S, Hope, W ORCID: 0000-0001-6187-878X, Campillo, N, Munoz-Bermudez, R, Sorli, L, Barcelo-Vidal, J, Gonzalez-Colominas, E, Alvarez-Lerma, F, Masclans, JR, Montero, M
et al (show 2 more authors) (2019) Population Pharmacokinetics of Anidulafungin in Critically III Patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63 (7). e00378-e00319.

[img] Text
Manucript-pdf-sended-before-acceptance.pdf - Author Accepted Manuscript

Download (1MB) | Preview


A two-compartment pharmacokinetic (PK) population model of anidulafungin was fitted to PK data from 23 critically ill patients (age, 65 years [range, 28 to 81 years]; total body weight [TBW], 75 kg [range, 54 to 168 kg]). TBW was associated with clearance and incorporated into a final population PK model. Simulations suggested that patients with higher TBWs had less-extensive MIC coverage. Dosage escalation may be warranted in patients with high TBWs to ensure optimal drug exposures for treatment of <i>Candida albicans</i> and <i>Candida glabrata</i> infections.

Item Type: Article
Uncontrolled Keywords: Candida, Monte Carlo simulation, anidulafungin, critical care unit, pharmacokinetics/pharmacodynamics
Depositing User: Symplectic Admin
Date Deposited: 05 Jun 2019 08:07
Last Modified: 13 Feb 2024 09:16
DOI: 10.1128/AAC.00378-19
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3044521